NEUROCRINE
Live / Registered — Registered (as of 15 Sept 2026)
What this means for you
Registered since 15 Sept 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 15 Sept 2032: the §8 declaration of use).
Record
- Serial number
- 98978962
- Registration number
- 8441670
- Mark type
- Word mark
- Filed
- 21 Sept 2023
- Published for opposition
- 18 Jun 2024
- Registered
- 15 Sept 2026
- Next maintenance filing
- §8 declaration of use, due by 15 Sept 2032 (grace period to 15 Mar 2033)
- Attorney of record
- Allison Strickland Ricketts
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment of endocrine, hormonal, and genetic diseases, disorders, and conditions; Pharmaceutical preparations for human use for the treatment of rare and orphan diseases, disorders, and conditions, namely, congenital adrenal hyperplasia
Owner
- Neurocrine Biosciences, Inc., San Diego, CA, US
- Neurocrine Biosciences, Inc., San Diego, CA, US
- Neurocrine Biosciences, Inc., San Diego, CA, US
Prosecution history
- 15 Sept 2026 — REGISTERED-PRINCIPAL REGISTER
- 08 Sept 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 08 Sept 2026 — REGISTERED-PRINCIPAL REGISTER
- 18 Aug 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 18 Aug 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 18 Aug 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 17 Aug 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 17 Aug 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 11 Aug 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 28 Jul 2026 — USE AMENDMENT FILED
- 11 Aug 2026 — DIVISIONAL PROCESSING COMPLETE
- 29 Jul 2026 — DIVISIONAL REQUEST RECEIVED
- 28 Jul 2026 — TEAS REQUEST TO DIVIDE RECEIVED
- 28 Jul 2026 — TEAS STATEMENT OF USE RECEIVED
- 26 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED